Virksomheden fremlagde også oplysninger om anvendelsen af Fendrix til levertransplanterede patienter, men trak ansøgningen om anvendelse af Fendrix til disse patienter tilbage under behandlingen af ansøgningen.
The company also presented data on the use of Fendrix in liver transplant patients, but it withdrew the application for the use of Fendrix in these patients during the assessment.